Asciminib Frontline Risk Adapted

Study acronym: ARTIST
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.
Trial Details
NCT Number NCT07804901
Lead Sponsor Prof. Dr. med. Andreas Hochhaus
Conditions
(from sponsor)		 Chronic Myeloid Leukemia (CML)
Related terms Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov